Trends in Primary- and Metastasis-Directed Radiotherapy Uptake and Survival in Metastatic Prostate Cancer
: Pivotal clinical trials temporally align with shifts in radiotherapy practices among M1 disease subgroups. The potential survival benefit of radiotherapy to the primary site and to metastases among patients with metastatic disease merits further investigation in the real-world setting. Further work may highlight differences in patient populations or overall efficacy of radiotherapy in these populations.
Authors
- Puneeth Iyengar (ORCID: https://orcid.org/0000-0003-3740-7915)
- Tej A. Patel (ORCID: https://orcid.org/0000-0002-0882-2960)
- Daniel Gorovets (ORCID: https://orcid.org/0000-0003-0529-0812)
- Himanshu Nagar (ORCID: https://orcid.org/0000-0003-2381-6910)
- Miranda B. Lam (ORCID: https://orcid.org/0000-0001-7885-6317)
- Edward Christopher Dee (ORCID: https://orcid.org/0000-0001-6119-0889)
- S. McBride
- James O. Suggitt
- Paul L. Nguyen
- Irini Yacoub
- Jonathan E. Leeman
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- University of Oxford (GB)
- New York Proton Center (US)
- Dana-Farber Brigham Cancer Center (US)
- New York University (US)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-04-15
- DOI
- https://doi.org/10.3390/jcm15083010
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute